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Results: SBRT treatment: maximum small bowel and 
duodenum dose-volume constraints were exceeded in 5/30 
(16.7%) and 2/30 (6.7%), respectively. Dose to OARs was: 
small bowel: Dmax 31.5-40.5 Gy, V30 0.2-13.4 cc; duodenum: 
Dmax 35.7-36.6 Gy, V30 2.1-3.7 cc. 
SBRS treatment: maximum small bowel and duodenum dose-
volume constraints were exceeded in 2/21 patients (9.5%) 
and 1/21 patient (4.7%), respectively. Dose to OARs was: 
small bowel: Dmax 15.6-16.3 Gy, V12 1.7-8.5 cc; duodenum 
Dmax 16.0 Gy, V12 0.1 cc. 
With a median follow up of 24 months after SBRT and 18 
months after SBRS, no early or late severe toxicity was 
observed in patients in whom constraints were not respected. 
 
Conclusion: Patients irradiated on small bowel and 
duodenum did not develop severe toxicity although the 
administered doses were above constrains proposed in 
literature. A prolonged follow-up and a larger population are 
needed to confirm the safety of dose-volume constraints 
other than those reported in literature about SBRT and SBRS 
on abdominal area. 
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Purpose or Objective: To define the maximum tolerated 
dose (MTD) of extra-cranial stereotactic treatment (SBRT) in 
previously irradiated patients. 
 
Material and Methods: In a dose escalation (Phase I) study, 
previously irradiated patients were enrolled in two different 
arms depending on treatment site and previous dose: 1) 
retreatment with previous dose > 60 Gy or retreatment of 
pancreatic and pelvic tumors, 2) retreatment with previous 
dose < 60 Gy. SBRT was delivered in 5 fractions with static 3D 
technique (4 non-coplanar beams) or dynamic arc (VMAT). 
The dose was prescribed at the isocenter. The Planning 
Target Volume (PTV) was defined as the GTV + 5-15 mm 
margin. According to the study arm, the first cohort of 6 
patients received a dose of 20 or 25 Gy, and subsequent 
cohorts of patients received doses up to 40 Gy. The dose 
limiting toxicity (DLT) was defined as any acute and late 
toxicity Grade ≥ 3. The MTD was defined a s the dose level 
with 2/6 or 4/12 DLT. 
 
Results: From September 2004 to December 2014, 51 
patients (M/F: 27/24; median age 65, range 44-87), 
previously irradiated with doses of 30 to 87 Gy (median dose 
50 Gy) were enrolled, after 4-228 months from the first 
treatment (median 11 months). Sixty-six lesions were treated 
(23 primary lesions or relapses, 43 lymphadenopathies) 
mainly from gynecological tumors (30%), followed by 
gastrointestinal tumors (26%) and prostatic tumors (17%). 
Nineteen of the 66 lesions were in the neck or chest, 22 in 
the abdomen and 25 in the pelvis. With a median follow-up of 
19 months (3-104), an overall response rate of 81% (Complete 
Response: 55%, Partial Response: 26%), with only 3% of 
disease progression was recorded. At 40 Gy dose-level, only 1 
patient showed DLT (cutaneous fistula in the sacral region). 
Two-year local control was 75% and 2-year metastasis-free 
survival was 30%. 
 
Conclusion: SBRT treatment in 5 fractions up to a dose of 40 
Gy is well tolerated in previously irradiated patients. This 
dose escalation protocol is still ongoing (Table 1). 
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Purpose or Objective: To define the maximum tolerated 
dose (MTD) of stereotactic extracranial radiosurgery 
performed in a single session (SBRS) in different clinical 
settings. 
 
Material and Methods: Based on a Dose Escalation study 
(Phase I), oligometastatic patients were enrolled in 4 
different arms depending on site and treatment purpose: 1) 
liver metastases, 2) lung metastases, 3) lymph node 
metastases or liver or lung metastases with a prolonged local 
control purpose, 4) bone metastases (non-vertebral). Dose 
was prescribed according to the Rosel protocol (V100 >95%, 
V90 >99% and Dmax <140% of the prescription) with dynamic 
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volumetric intensity modulated arc technique (VMAT). The 
Planning Target Volume (PTV) was defined as the GTV plus a 
personalized Internal Margin and a 3 mm Set -up Margin. 
Based on the study arm, the first cohort of 6 patients 
received a dose of 12-26 Gy, and the subsequent cohorts of 
patients received doses up to 30 Gy. The dose limiting 
toxicity (DLT) was defined as any acute and > Grade 3 late 
toxicity (CTC-AE v. 4.03). In case of 2/6 or 4/12 DLT in the 
analyzed cohort, this dose was considered as MTD. 
 
Results: From August 2010 to April 2015 92 patients were 
enrolled (M/F: 50/42; median age: 67 years (40-93); range: 
40-93) and 142 lesions were treated (bone: 47, lung: 39, 
nodes: 33, and liver: 23) mainly from prostatic (28%), 
gastrointestinal (25%), breast (21%), and gynecological (8%) 
tumors. With a median follow-up of 11 months (2-58 ), 
overall response rate was 70 % (CR: 47%, PR: 23%), with 15% 
stable disease and only 4% of progressive disease (15 lesions 
(11%) not evaluable for response at the time of the analysis). 
No DLT was recorded. Two-year local control at was 77% and 
2-year metastases-free survival was 34%. Two-year overall 
survival was 78%. 
 
Conclusion: SBRS is well tolerated up to a dose of 30 Gy. The 
dose escalation protocol is ongoing (Table). 
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Purpose or Objective: Vertebral compression fracture (VCF) 
by involvement of metastatic tumor significantly 
compromises in quality of life of patients. Spinal Instability 
Neoplastic Score (SINS) is the classification system to predict 
VCF, but lacks clinical validation. The purpose of this study 
was to develop a novel simple method predicting the risk of 
VCF and compare its effectiveness with SINS. 
 
Material and Methods: A total of 225 vertebral segments in 
154 patients treated with palliative radiotherapy from Sep 
2011 to Aug 2013 were included for analysis. VCF was defined 
as occurrence or progression of collapse deformity within 
treated vertebral segments. Each segment was scored by 
SINS. In addition to 6 SINS components, we also evaluated the 
impact of paraspinal tumor extension, epidural extension, 
tumor origin, performance status, and radiotherapy-related 
factors on VCF risk. Recursive partitioning analyses (RPA) was 
used to identify optimal classification of risk groups. 
 
Results: The median follow-up was 8.5 months. The 6-month 
and 12-month VCF-free probability was 83.3% and 77.3%, and 
median survival was 10 months. Multivariate analysis 
identified paraspinal tumor extension (P=0.03) and baseline 
vertebral body collapse (P<0.001) were independent 
predictors for VCF. All SINS criteria except body collapse 
were not significant for VCF. The RPA defined 3 risk groups. 
The lowest risk group (n=96) were vertebrae with less than 
50% body involved by tumor and no collapse. The 
intermediate risk group (n=90) were vertebrae with more 
than 50% body involved and no collapse, or vertebrae with 
body collapse and no paraspinal tumor extension. The highest 
risk group (n=39) were vertebrae with body collapse and 
paraspinal extension. The 6-month VCF-free probability for 
each groups were 93.5%, 84.9%, and 53.7%, respectively 
(P<0.001). According to the SINS classification, the 6-month 
VCF-free probabilities were 91.9% (stable group, n=78), 81.9% 
(potentially unstable group, n=122), and 62.8% (unstable 
group, n=25) (P<0.001). 
 
Conclusion: Not all the components of SINS were significant 
predictors of VCF. It is feasible to estimate VCF by the 
simpler RPA stratification. 
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Purpose or Objective: The purpose of this randomized 
clinical trial was to estimate prognostic factors predicting 
symptom control after radiotherapy in patients with painful 
bone metastases. 
 
Material and Methods: 640 cases of symptomatic bone 
metastases treated with EBRT were analyzed. The primary 
tumor sites were breast (419), prostate (52), lung (50), renal 
(37), colon (13), melanoma (8), sarcomas (7) and others 
including bladder, thyroid, uterus, carcinoid (54). The lesions 
of spine and pelvis predominated (48% and 30% 
correspondingly). Pathological fractures in treatment area 
were observed in 72,3% for spinal metastases and in 22,2% for 
long bones lesions. The average pain intensity was 2,2 by the 
four-point verbal scale and proved significantly lower for 
carcinoid tumors. Treatment schedules included 2, 3 and 4 
fractions of 6,5 Gy and standard treatment schedule with 23 
fractions of 2 Gy. 
 
Results: The average follow-up period was 70 months. 
Overall effectiveness of EBRT - 96,1%. Complete response 
rate (CRR) - 59,1%. The pain relapse rate - 8,7%. CRR for 
standard treatment schedule was 77,4% and significantly 
decreased from 64,4% to 47,9% and 43,6% for 4, 3 and 2 
fractions of 6,5 Gy correspondingly (p<0,05). There was no 
correlation between treatment schedules and pain relapse 
rate. CRR in patients with low initial pain intensity was 
87,3%, with moderate pain – 59,8% and intense pain – 42% 
(p<0,01). CRR for spine and pelvis lesions was 63,4% and 
59,3%, for long bones metastases - 48,3% and significantly 
decreased for sacrum isolated metastases – 27,8% (р<0,01). 
The frequency of pathological fractures in treatment area 
detected no correlation with CRR. High radiosensitivity was 
revealed for bone metastases of carcinoid with CRR 100%, 
melanoma – 75%, breast cancer – 64%, prostate cancer – 59,6% 
and sarcomas – 57,1%. Bone metastases of lung, colon, and 
renal cancer turned to be radioresistance (44%, 30,1% and 
27% correspondingly). Analysis of variance (ANOVA) revealed 
several factors affecting CRR: tumor primary site (p<0,001), 
total dose (p<0,001), initial pain intensity (p<0,001), 
localization of metastases in skeleton (p<0,02). In the 
multifactorial analysis MANOVA tumor primary site and pain 
intensity before radiotherapy were the only independent 
prognostic factors of CRR.  
 
Conclusion: Tumor primary site, initial pain intensity, total 
dose, localization of metastases in skeleton are clinical 
predictors of radiosensitivity of bone metastases, they 
significantly affect the CRR. 
 
 
 
